MedPath

Namodenoson Shows Promise in Treating Decompensated Liver Cirrhosis: Patient's Remarkable Recovery in Compassionate Use Program

• A patient with decompensated liver cirrhosis demonstrated significant clinical improvement after 20 months of Namodenoson treatment, including resolution of moderate ascites and no further variceal bleeding episodes.

• Can-Fite BioPharma's Namodenoson emerges as a potential breakthrough for decompensated cirrhosis patients, addressing a critical gap in treatment options beyond liver transplantation.

• The development holds significant promise for the estimated 10.6 million people globally affected by decompensated cirrhosis, targeting a U.S. market projected to reach $15 billion by 2030.

In a significant breakthrough for liver disease treatment, Can-Fite BioPharma has reported remarkable clinical improvements in a patient with decompensated liver cirrhosis treated with Namodenoson under a compassionate use program. The development offers new hope for patients facing limited treatment options beyond liver transplantation.

Clinical Response and Symptom Improvements

After 20 months of treatment, the patient experienced substantial improvements across multiple disease markers. Notable developments include:
  • Complete resolution of moderate ascites, eliminating the need for diuretics for over a year
  • No recurrence of esophageal variceal bleeding episodes
  • Significant reduction in fatigue and edema
  • Measurable decrease in liver stiffness compared to pre-treatment levels
  • Declining globulin levels, indicating improvement in liver function

Expert Perspective on Treatment Impact

Dr. Ohad Etzion, Chief of Gastrointestinal and Liver Diseases at Soroka Medical Center in Israel, emphasized the significance of these results: "The patient's positive response to Namodenoson is extremely encouraging. We currently have very limited options for treating patients with decompensated liver disease beyond liver transplantation. Unfortunately, due to a shortage of donor organs, many patients die while waiting for a transplant."

Disease Burden and Market Need

The development addresses a critical medical need in liver disease treatment:
  • Global impact: An estimated 10.6 million people affected by decompensated cirrhosis as of 2017
  • Limited options: Current treatment landscape restricted primarily to liver transplantation
  • Organ shortage: Extended waiting periods for transplants, often exceeding five years
  • Market potential: U.S. liver cirrhosis treatment market projected to reach $15 billion by 2030

About Namodenoson

Namodenoson is an orally administered small molecule drug that specifically targets the A3 adenosine receptor (A3AR). The drug's development program includes:
  • Ongoing pivotal Phase III trial for advanced liver cancer
  • Phase IIb trial for Metabolic Dysfunction-associated Steatohepatitis (MASH)
  • Phase IIa study in pancreatic cancer
The drug's selective binding to A3AR, which is highly expressed in diseased cells but minimal in normal cells, contributes to its favorable safety profile. This characteristic makes it particularly promising for long-term treatment of chronic liver conditions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Grants Accelerated Approval to Ipsen's Iqirvo, First Dual PPAR Agonist for Primary Biliary Cholangitis

Ipsen's Iqirvo (elafibranor) receives FDA accelerated approval as the first dual PPAR alpha/delta agonist and first new therapy in over a decade for primary biliary cholangitis treatment.
In the ELATIVE trial, Iqirvo demonstrated significant efficacy with 51% of patients achieving cholestasis response compared to 4% on placebo, marking a substantial therapeutic advancement.

Liver Cirrhosis Clinical Trial Pipeline Gains Momentum

The liver cirrhosis treatment market is experiencing significant growth, driven by advancements in antiviral therapies and regenerative medicine. Over 30 companies are actively developing new treatments, with several promising therapies currently in clinical trials.

alfapump System Demonstrates Ascites Control and Improved Quality of Life in Cirrhosis Patients

The alfapump system effectively controls ascites in patients with decompensated cirrhosis, reducing or eliminating the need for therapeutic paracentesis.
Patients using the alfapump experienced a significant improvement in their quality of life, including an average of 10 additional good health days per month.

Can-Fite's Namodenoson Shows Liver Protection and Anti-Cancer Activity in HCC

Can-Fite BioPharma's Namodenoson demonstrates liver-protective effects alongside its anti-cancer activity in hepatocellular carcinoma (HCC).
A Phase 3 trial is underway for Namodenoson in advanced liver cancer, with promising results including one patient cancer-free for over 8 years.

Can-Fite Doses First Patient in Phase IIa Pancreatic Cancer Trial with Namodenoson

Can-Fite BioPharma has dosed the first patient in its Phase IIa clinical trial evaluating Namodenoson for advanced pancreatic adenocarcinoma.
The open-label, multicenter trial will assess the safety, clinical activity, and pharmacokinetics of oral Namodenoson (25 mg twice daily) in patients who have progressed on first-line therapy.

Can-Fite BioPharma Doses First Patient in Phase IIa Pancreatic Cancer Trial with Namodenoson

Can-Fite BioPharma has dosed the first patient in its Phase IIa clinical trial (NCT06387342) evaluating Namodenoson for advanced pancreatic adenocarcinoma.
The open-label, multicenter trial will assess the safety, clinical activity, and pharmacokinetics of oral Namodenoson (25 mg twice daily) in patients who have progressed on first-line therapy.

Can-Fite Doses First Patient in Phase IIa Pancreatic Cancer Trial with Namodenoson

Can-Fite BioPharma has dosed the first patient in a Phase IIa clinical trial evaluating Namodenoson for advanced pancreatic adenocarcinoma.
The open-label, multicenter trial will assess the safety, clinical activity, and pharmacokinetics of oral Namodenoson in patients who have progressed on first-line therapy.

Can-Fite's Namodenoson Receives Patent Allowance in Australia and US for Anti-Obesity Use

Can-Fite BioPharma's Namodenoson receives patent allowance in Australia and the US for treating obesity, expiring in 2040 and 2042, respectively.
The patent covers methods of treating obese patients using an oral formulation of Namodenoson, an A3 adenosine receptor ligand.

Can-Fite BioPharma Advances Clinical Trials for Psoriasis, HCC, and NASH

Can-Fite BioPharma focuses on orally bioavailable small molecule therapeutics for cancer, liver, and inflammatory diseases.
Piclidenoson is in Phase III clinical trials for psoriasis, showing promise in treating this chronic skin condition.

Sequana Medical Receives FDA IDE Approval to Commence alfapump Pivotal Study for Refractory Ascites

Sequana Medical received unconditional FDA IDE approval for the POSEIDON pivotal study, evaluating the alfapump for recurrent or refractory ascites due to liver cirrhosis.
The POSEIDON study is a single-arm, open-label, crossover study that will enroll up to 50 patients in the study cohort across U.S. and Canadian centers.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy